Sign up to access all valuation multiples
AOTI Inc produces, rents, and sells medical devices to help resolve severe acute and chronic wounds for customers globally. The company provides efficacious topical wound oxygen solutions for use in both the institutional and the home care setting to improve the health, well-being, and independence of patients. Its products include TWO2 Extremity Chamber, TWO2 Multi-Patch.
2008
n/a
LTM Revenue $48.8M
LTM EBITDA $5.7M
$61.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, AOTI reported last 12-month revenue of $48.8M and EBITDA of $5.7M.
In the same period, AOTI achieved $1.4M in LTM net income.
See AOTI valuation multiples based on analyst estimatesIn the most recent fiscal year, AOTI reported revenue of $77.8M and EBITDA of $3.5M.
AOTI expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AOTI valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $48.8M | XXX | $77.8M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $68.5M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $5.7M | XXX | $3.5M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 5% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $1.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $1.4M | XXX | -$2.3M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | -3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AOTI has current market cap of GBP 40.7M (or $54.3M), and EV of GBP 45.9M (or $61.2M).
As of October 17, 2025, AOTI's stock price is GBP 0 (or $0).
See AOTI trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $61.2M | $54.3M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAOTI's trades at 0.8x EV/Revenue multiple, and 17.4x EV/EBITDA.
See valuation multiples for AOTI and 15K+ public compsAs of October 17, 2025, AOTI has market cap of $54.3M and EV of $61.2M.
Equity research analysts estimate AOTI's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AOTI has a P/E ratio of 30.2x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $54.3M | XXX | $54.3M | XXX | XXX | XXX |
| EV (current) | $61.2M | XXX | $61.2M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 17.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 36.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.2x | XXX | -23.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAOTI's last 12 month revenue growth is 19%
AOTI's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
AOTI's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AOTI's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AOTI and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 9% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 86% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AOTI acquired XXX companies to date.
Last acquisition by AOTI was XXXXXXXX, XXXXX XXXXX XXXXXX . AOTI acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was AOTI founded? | AOTI was founded in 2008. |
| Where is AOTI headquartered? | AOTI is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| Who is the CEO of AOTI? | AOTI's CEO is Dr. Michael Stephen Griffiths. |
| Is AOTI publicy listed? | Yes, AOTI is a public company listed on LON. |
| What is the stock symbol of AOTI? | AOTI trades under AOTI ticker. |
| When did AOTI go public? | AOTI went public in 2024. |
| Who are competitors of AOTI? | Similar companies to AOTI include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of AOTI? | AOTI's current market cap is $54.3M |
| What is the current revenue of AOTI? | AOTI's last 12 months revenue is $48.8M. |
| What is the current revenue growth of AOTI? | AOTI revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of AOTI? | Current revenue multiple of AOTI is 0.9x. |
| Is AOTI profitable? | Yes, AOTI is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AOTI? | AOTI's last 12 months EBITDA is $5.7M. |
| What is AOTI's EBITDA margin? | AOTI's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of AOTI? | Current EBITDA multiple of AOTI is 8.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
